Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVZY0X)

• Drug Name: TNP-ATP Drug Info
• Synonyms: 2',3'-O-(2,4,6-trinitrophenyl)-ATP

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3035228
  CAS Number: CAS 61368-63-6
  TTD Drug ID: DMVZY0X

Molecule-Related Drug Atlas

Drug(s) Targeting P2X purinoceptor 3 (P2RX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefapixant	DM4GWL7	Cough	MD12	Phase 3	[3]
BAY-1902607	DMYSQMW	Cough	MD12	Phase 2	[3]
BAY 1902607	DMFA4CK	Cough	MD12	Phase 1/2	[3]
AF-130	DM8LG2I	Hypertension	BA00-BA04	Phase 1	[4]
BAY-1817080	DMNL5G7	Endometriosis	GA10	Phase 1	[3]
BAY 1817080	DMF9ALP	Cough	MD12	Phase 1	[5]
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[6]
ISOPPADS	DMWI0M8	Discovery agent	N.A.	Investigative	[7]
LVAYPWT	DMIO405	Discovery agent	N.A.	Investigative	[8]
MK-3901	DM5EQ7F	Pain	MG30-MG3Z	Investigative	[6]

Drug(s) Targeting P2X purinoceptor 1 (P2RX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[9]
L-betagamma-meATP	DMTNQCE	Discovery agent	N.A.	Investigative	[9]
MRS 2219	DM7IK68	Discovery agent	N.A.	Investigative	[10]
NF023	DMJ4GO9	Discovery agent	N.A.	Investigative	[9]
NF449	DM816Z2	Discovery agent	N.A.	Investigative	[11]
Ip5I	DMB2YXN	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 1 (P2RX1)	TTJW7B3	P2RX1_HUMAN	Antagonist	[2]
P2X purinoceptor 3 (P2RX3)	TT2THBD	P2RX3_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4324).
• [2] Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
• [3] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
• [7] Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
• [8] Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
• [10] A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
• [11] Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.